Working to Eradicate Gynecologic Cancers

PS5
Featured Poster Session V: Clinical Trials/Drug Repurposing

Monday, March 24, 2014: 7:00 AM-8:00 AM
Room 13-16 (Tampa Convention Center)
Description:
Featured Poster Session Moderator:  Carolyn Muller, MD, University of New Mexico, Albuquerque, Albuquerque, NM
7:00 AM
Moderator Introductions
C. Muller
University of New Mexico, Albuquerque, Albuquerque, NM
 
7:05 AM
94 - Featured Poster
Impact of age on tolerance of chemoradiation and survival for patients with local regionally advanced cervical cancer: a pooled analysis of Gynecologic Oncology Group (GOG) phase III trials
K. N. Slaughter1, J. Java2, F. B. Stehman3, P. G. Rose4, K. N. Moore1 and P. A. DiSilvestro5
1The University of Oklahoma, Oklahoma City, OK, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Indiana University School of Medicine, Indianapolis, IN, 4Cleveland Clinic, Cleveland, OH, 5Women & Infants Hospital, Brown University, Providence, RI
 
7:07 AM
95 - Featured Poster
Do elderly women with endometrial cancer qualify for existing clinical trials?
L. H. Clark1, A. L. Jackson1, V. L. Bae-Jump1, P. A. Gehrig1, L. Van Le1 and E. M. Ko2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of Pennsylvania, Philadelphia, PA
 
7:09 AM
96 - Featured Poster
Patient and physician factors associated with participation in Gynecologic Oncology Group (GOG) trials in cervical and uterine cancer
S. E. Brooks1, R. L. Carter2, S. C. Plaxe3, K. M. Basen-Engquist4, M. Rodriguez5, J. L. Walker6, T. K. N. Myers7, J. G. Drake8, L. J. Havrilesky9, C. L. Brown10, L. Van Le11 and L. M. Landrum6
1Norton Healthcare, Louisville, KY, 2University at Buffalo and Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5Northern Indiana Cancer Research Consortium, Mishawaka, IN, 6The University of Oklahoma, Oklahoma City, OK, 7Baystate Medical Center, Longmeadow, MA, 8Waukesha Memorial Hospital, Waukesha, WI, 9Duke University Medical Center, Durham, NC, 10Memorial Sloan Kettering Cancer Center, New York, NY, 11University of North Carolina at Chapel Hill, Chapel Hill, NC
 
7:11 AM
Discussant
J. L. Walker
The University of Oklahoma, Oklahoma City, OK
 
7:16 AM
97 - Featured Poster
A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: a GOG study
R. D. Alvarez1, M. Sill2, S. A. Davidson3, C. Muller4, D. P. Bender5, R. DeBernardo6, K. Behbakht3 and W. K. Huh1
1University of Alabama at Birmingham, Birmingham, AL, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Colorado Denver, Aurora, CO, 4University of New Mexico, Albuquerque, Albuquerque, NM, 5University of Iowa Hospitals and Clinics, Iowa City, IA, 6Cleveland Clinic, Cleveland, OH
 
7:18 AM
98 - Featured Poster
Phase I trial results of a folate receptor alpha-directed cancer vaccine (E39) in ovarian and endometrial cancer patients to prevent recurrence
K. A. Byrd1, E. Schneble2, S. Ponniah3, W. P. McGuire4, T. P. Conrads5, J. C. Elkas6, K. M. Darcy5, G. L. Maxwell4, C. A. Hamilton7 and G. Peoples2
1Naval Medical Center Portsmouth, Portsmouth, VA, 2San Antonio Military Medical Center, Ft Sam Houston, TX, 3Uniformed Services University of the Health Sciences, Bethesda, MD, 4Inova Fairfax Hospital, Falls Church, VA, 5Gynecologic Cancer Center of Excellence, Annandale, VA, 6Mid Atlantic Pelvic Surgery Associates, Annandale, VA, 7Walter Reed National Military Medical Center, Bethesda, MD
 
7:20 AM
99 - Featured Poster
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study
B. J. Monk1, P. Ghatage2, T. Parekh3, E. Henitz3, R. Knoblauch3, A. Soto Matos-Pita4, A. Nieto4, Y. C. Park3, D. Ricci3 and A. Poveda5
1University of Arizona Cancer Center, Phoenix, AZ, 2Tom Baker Cancer Centre, Calgary, AB, Canada, 3Janssen Research & Development, Raritan, NJ, 4PharmaMar SA, Madrid, Spain, 5Fundación Instituto Valenciano de Oncología, Valencia, Spain
 
7:22 AM
100 - Featured Poster
Phase II trial of pemetrexed and carboplatin in platinum-sensitive recurrent ovarian, Fallopian tube, and primary peritoneal cancer
A. R. Van Arsdale1, M. H. Einstein1, M. A. Brewer2, P. F. Timmins III3, J. D. Wright4, A. L. Leiser5, A. B. Astrow6, S. Cohen7, G. L. Goldberg1 and D. Y. S. Kuo1
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2University of Connecticut Health Center, Farmington, CT, 3Women's Cancer Care Associates, Albany, NY, 4Columbia University College of Physicians and Surgeons, New York, NY, 5Beth Israel Medical Center, New York, NY, 6Maimonides Medical Center, Brooklyn, NY, 7Roosevelt Hospital, New York, NY
 
7:24 AM
101 -Featured Poster
Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
T. J. Herzog1, G. E. Richardson2, B. J. Monk3, B. Y. Karlan4, C. Marth5, L. Navale6, D. J. Warner6 and A. M. Oza7
1Columbia University College of Physicians and Surgeons, New York, NY, 2Cabrini Hospital, Melbourne, Australia, 3University of Arizona Cancer Center, Phoenix, AZ, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5Medical University Innsbruck, Innsbruck, Austria, 6Amgen Inc., Thousand Oaks, CA, 7Princess Margaret Hospital, Toronto, ON, Canada
 
7:26 AM
Discussant
C. Muller
University of New Mexico, Albuquerque, Albuquerque, NM
 
7:31 AM
102 - Featured Poster
Not your mother's bisphosphonate: targeting angiogenesis in ovarian cancer
H. J. Dalton1, N. M. Reusser1, A. Zien2, R. A. Previs1, R. Rupaimoole1, B. Zand1, J. N. Bottsford-Miller1, A. M. Nick1, R. L. Coleman1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Molecular Health GmbH, Heidelberg, Germany
 
7:33 AM
103 - Featured Poster
Aspirin and acetaminophen decrease the risk of cervical cancer in long-term users
C. Liu1, G. Friel2, N. V. Kolomeyevskaya2, S. B. Lele2, K. O. Odunsi2 and K. Moysich2
1SUNY University at Buffalo and Roswell Park Cancer Institute, Buffalo, NY, 2Roswell Park Cancer Institute, Buffalo, NY
 
7:35 AM
104 -Featured Poster
Endometrial cancer outcomes in diabetic women treated with metformin, statins, and aspirin
S. R. Pierce1, K. M. Doll2, B. Davidson3, C. Lee1, E. M. Ko4, A. C. Snavely1, P. A. Gehrig1, A. A. Secord3, L. J. Havrilesky3 and V. L. Bae-Jump1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, Chapel Hill, NC, 3Duke University Medical Center, Durham, NC, 4University of Pennsylvania, Penn Medicine, Philadelphia, PA
 
7:37 AM
105 - Featured Poster
Metformin has increased efficacy under obese conditions in a novel genetically engineered mouse model of serous ovarian cancer
A. L. Jackson, Y. Zhong, C. Zhou, J. E. Kilgore, L. Makowski, P. A. Gehrig and V. L. Bae-Jump
University of North Carolina at Chapel Hill, Chapel Hill, NC
 
7:39 AM
Discussant
C. Muller
University of New Mexico, Albuquerque, Albuquerque, NM
 
7:44 AM
Question & Floor Discussion
 
See more of: Featured Poster Session
<< Previous Course | Next Course >>